Lytix Biopharma AS Announces Approval by Hungarian Authorities and Ethics Committee to Start Phase IIa Clinical Trial with

TROMSØ & OSLO, Norway--(BUSINESS WIRE)-- The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with LytixarTM (LTX-109) treatment of skin infections caused by Gram positive bacteria.

According to Lytix Biopharma CEO Gunnar Sælid, “We are delighted to announce the approvals by the Hungarian Regulatory Authorities and appropriate Ethics Committee to test our novel antimicrobial drug LytixarTM (LTX-109) in patients whom have skin infections caused by Gram positive bacteria. Skin infections caused by Gram positive bacteria are an ideal patient group in which to test our antimicrobial drug. Standard of care for these types of infections is generally topical drugs, representing a significant market. Since bacteria such as Staphylococcus aureus are often resistant to the exisiting drugs including methicillin-resistance (methicillin-resistant Staphylococcus aureus - MRSA), there is a clear need for a novel drug such as LytixarTM. For the Company this is an important study, validating the clinical utility of our novel, broad-spectrum, antimicrobial drug LytixarTM.”

Preclinical models have demonstrated that LytixarTM is strongly bactericidal, being equally effective against wild-type as well as drug-resistant bacteria such as MRSA. Because of its unique membrane-lysing mechanism of action, there is no cross-resistance to other drugs. It has also proven highly unlikely for bacteria to develop new resistance to the drug.

”The current study will be run at four hospital dermatology clinics in Hungary. Patients with confirmed Gram positive skin infections will be included in the study and randomized to receive either active drug or placebo in cohorts at ascending dose levels. LytixarTM (LTX-109) has the potential to become a valuable new antimicrobial agent for Gram positive skin infections as well as in a range of other indications”, concludes Dr. Wenche Marie Olsen, COO and Director of Product Development, Infectious diseases, at Lytix Biopharma AS.



CONTACT:

Corporate Inquiries
Gunnar Sælid, CEO
Tel +47 911 92 330
or
Anders Fugelli, Director, Business Development
Tel +47 924 81 432
[email protected]
or
Media Inquiries
Richard Hayhurst, Schwartz Communications
Tel +44 (0) 7950 878218
Email: [email protected]

KEYWORDS:   Europe  Norway  Hungary

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.